Résumé
L’hémoglobinurie paroxystique nocturne est une maladie liée à une mutation somatique entraînant l’expansion de clones cellulaires déficients pour des molécules d’ancrage de protéines de surface cellulaire. Plusieurs formes d’expression de ces mutations peuvent être rencontrées avec des implications diagnostiques et thérapeutiques différentes. La technologie recommandée pour poser le diagnostic et surveiller les patients, est la cytométrie de flux. Cependent l’approche technologique est différente, s’il s’agit de diagnostiquer une hémoglobinurie paroxystique nocturne (HPN) classique ou maladie de Machiavela-Micheli, ou identifier une petite souspopulation associée à une insuffisance médullaire, la pathologie dans ce cas intéressant des cellules non HPN.
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a disease linked to a somatic mutation which is accompanied by expansion of cell clones deficient in molecules needed to make cell membrane anchors for proteins. These mutations can be found in diverse forms, resulting in differing diagnostic and therapeutic implications. Flow cytometry is the recommended technology for confirming diagnosis and monitoring patients. However, the technological approach differs according to whether the aim is to diagnose classic PNH (Marchiafava-Micheli syndrome) or identify one of the sub-populations that can occur in cases of bone marrow failure, where the disease affects PNH cells.
Références
Dacie JV, Lewis SM. Paroxysmal noctural haemoglobinuria; clinical manifestatons, haematology, and nature of the disease. Ser. Haematol. 1972; 5:3–23
Takeda J, Miyata T, Kawagoe K et al. Deficiency of a GPI anchor caused by somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–711
Parker C, Omine M, Richards S et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–3709
Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinicla significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902
Schubert J, Alavarado M, Uciechowski P et al. Diagnosis of paroxysmal nocturnal haemoglobinuria using immunophenotyping of preripheral blood cells. Br. J. Haematol. 1991;79:487–492
Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry. 2000;42:223–233
Hall SE, Rowe WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:5332–5340
Yamashina M, Ueda E, Kinoshita T et al. Inherited complete deficiency of 20 kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1990;323:1184–1189
Nakao S, Wang H, Chuhjo T. Clinical significance of increased PNH-type cells in the peripheral blood of patients with aplastic anemia and refractory anemia. In: Omine M, Kinoshita D, eds. Paroxysmal Nocturnal Hemoglobinuria and Related Disorders: Molecular Aspects of Pathogenesis. Tokyo:Springer; 2003: 129–138
Diep DB, Nelson KL, Raja SM et al. Glycosylphosphatidylinositol anchors of membrane glycoproteins are binding determinants for the channel-forming toxin aerolysin. J Biol Chem. 1998;273:2355–2360
Mukhina GL, Buckley JT, Barber JP et al. Multilineage glycosilphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. Br. J Haematol. 2001;115:476–482
Luzzatto L, Nafa K, Genetics of PNH. In Young NS, Moss I eds. Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins. San Diego, CA:Academic Press; 2000:21–47
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Genty, V., Dine, G. Surveillance et diagnostic de l’hémoglobinurie paroxystique nocturne en cytométrie de flux. Bio trib. mag. 27, 28–31 (2008). https://doi.org/10.1007/BF03029278
Issue Date:
DOI: https://doi.org/10.1007/BF03029278